---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pharmacodynamics"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pharmacodynamics. Topics: Adiponectin as a marker of PPARγ engagement: phase 1 multiple ascending dose study in healthy participants; Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin; Pharmacodynamic biomarkers used for dose selection; Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE; 7 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Adiponectin as a marker of PPARγ engagement: phase 1 multiple ascending dose study in healthy participants

> “After Group 6 of the SAD cohort completed evaluation, multiple ascending doses (MAD) of oral lanifibranor were administered to young healthy males for 14 days, progressing to a higher dose after the safety and tolerability of the previous dose was established”
> “Lanifibranor significantly increased adiponectin versus placebo at 400, 1000, and 1500 mg daily doses, with high–molecular weight (HMW) adiponectin increases at 1000 and 1500 mg daily (Figure 2 and Figure 3)”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.6.2-2"></a>

### Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin

> “The phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 28-day study evaluated lanifibranor in participants with T2DM who were on metformin monotherapy (Figure 1)”
> “Lanifibranor (400, 800, and 1400 mg) consistently induced dose- and time-related increases in total and HMW adiponectin (Figure 4), which is indicative of PPARγ engagement”
> “Exposures of about 50 µg·h/mL for area under the curve from time zero to the last measurable concentration (AUC0-τ) and about 7 µg/mL for the maximal concentration (Cmax) resulted in more than 200% increase for the percent change from baseline total adiponectin”
> “Dose-related improvements in insulin, pro-insulin, and insulin resistance were observed with lanifibranor, with a significant reduction in pro-insulin with 1400 mg versus placebo.”
> “Reductions in average and postprandial blood glucose were observed at 1400 mg (Table 2), which were consistent with the PPARγ insulin-sensitizing mechanism”
> “Lanifibranor 800 and 1400 mg showed significant (P<0.05) change from baseline in high-density lipoprotein (HDL) cholesterol and triglycerides compared with placebo (Figure 5 and Table 2)”
> “At Day 28, lanifibranor showed no fluid-retention signals (pedal edema, ankle foot volume, ankle circumference, or body-weight increase) versus placebo, with no changes in hematology, albumin, or brain natriuretic peptide (BNP; Table 3)”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

| Mean (SD) percent change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
| --- | --- | --- | --- | --- |
| Triglycerides | “–19.7 (33.9)” | “–20.8 (23.5)” | “–31.7 (31.2)” | “–5.81 (27.6)” |
| HDL-C | “13.4 (15.3)” | “16.7 (17.2)” | “27.7 (25.9)” | “2.52 (12.2)” |
| Pro-insulin | “–26.7 (35.6)” | “–21.1 (45.0)” | “–37.4 (26.3)” | “–3.28 (49.9)” |

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

| Mean (SD) value reported for change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
| --- | --- | --- | --- | --- |
| Ankle foot volume, cm3 | “3.75 (14.51)” | “–5.31 (15.51)” | “3.91 (11.14)” | “–5.42 (11.07)” |
| Body weight change at Day 28, kg | “0.55 (1.97)” | “0.11 (1.72)” | “0.94 (2.05)” | “–0.36 (2.68)” |
| Hemoglobin, g/L | “–5.63 (4.81)” | “–5.04 (6.75)” | “–5.96 (5.55)” | “–3.70 (5.29)” |

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### Pharmacodynamic biomarkers used for dose selection

> “Doses have been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study):”
> “The two doses chosen for the trial demonstrated significant improvement in biomarkers of PPAR α, γ and probably δ in diabetic patients.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE

> “This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.”
> “Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase.”
> “With placebo only 10% had moderate, and none high increase (Supplementary Table 6).”
> “Adiponectin is a pleiotropic adipokine and PPARγ downstream mediator, while PPARα activity may affect adiponectin signaling through receptor upregulation”
> “Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).”
> “Fasting high density lipoprotein cholesterol (HDL-C) increased significantly at treatment week 4 (TW4), maintained until EOT: patients receiving lanifibranor 1200 mg and 800 mg had an AMD at EOT of 0.10 mmol/L (95%CI: 0.03 to 0.16, p = 0.003, equivalent to 3.9 mg/dL) and 0.16 mmol/L (95%CI: 0.09 to 0.22, p < 0.001, equivalent to 6.2 mg/dL), respectively (Table 1).”
> “No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).”
> “From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]).”
> “Systolic BP did not change significantly.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

> “There was a dose-dependent increase in serum adiponectin level, which suggests that there was an improvement in adipose-tissue function.”
> “This improvement in adipose tissue function is most likely the main reason for the observed increase in body weight.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.6.2-5"></a>

### NT-proBNP, hemoglobin, and the PPARγ class history of edema and heart failure

> “While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.”
> “Past pure PPARγ agonists such as the thiazolidinediones pioglitazone and rosiglitazone are effective for glycemic control and improving IR, but also have been associated with an increased risk of edema and heart failure”
> “There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

> “A reduction in hemoglobin levels was observed in the lanifibranor groups, a finding that is consistent with those in previous reports of other compounds with PPARγ agonism; such a reduction has several potential underlying mechanisms.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.6.2-6"></a>

### Important risks identified for the PPAR agonist class

> “Clinical experience with medicinal products from the same therapeutic class identified the following important risks:”
> “Hypoglycemia”
> “Peripheral edema”
> “Heart failure”
> “Weight gain”
> “Anemia”
> “Some of these risks have been observed during clinical development with lanifibranor in patients with NASH, including peripheral edema, weight gain and anemia.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.6.2-7"></a>

### Plasma volume and cardiac effects in rats compared with rosiglitazone, muraglitazar, and tesaglitazar

> “In a 9-week head-to-head comparative study in rats aimed at evaluating side effects of PPAR agonists such as plasma volume expansion and secondary cardiac hypertrophy, or skeletal muscle toxicity, daily doses of lanifibranor up to 1000 mg/kg compared favorably with other PPAR agonists rosiglitazone, muraglitazar and tesaglitazar.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.2-8"></a>

### Hepatic, muscle, and adipose tissue insulin sensitivity by clamp: participants with type 2 diabetes and MASLD

> “In this single-center phase II study, 38 patients with type 2 diabetes and MASLD were randomized 1:1 to receive lanifibranor 800 mg or placebo for 24 weeks.”
> “The main prespecified secondary endpoint was the change in hepatic, muscle and adipose tissue insulin sensitivity using the gold-standard euglycemic hyperinsulinemic clamp technique to measure glucose turnover.”
> “Lanifibranor significantly improved hepatic and peripheral IR (i.e. fasting endogenous [primarily hepatic] glucose production, hepatic IR, and insulin-stimulated muscle glucose disposal or Rd).”
> “Secondary metabolic endpoints also improved (fasting glucose, insulin, HOMA-IR, HbA1c, HDL-C), and adiponectin increased 2.4-fold (all p <0.001).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-2.1.2.6.2-9"></a>

### Liver sinusoidal endothelial cell capillarisation in NATIVE liver biopsies

> “We analysed CD34 expression, a marker of LSEC capillarisation, on liver biopsies from patients considered for inclusion in the NATIVE trial at baseline (n = 249), and after 24 weeks of placebo or lanifibranor (n = 173).”
> “In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A).”
> “Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C).”
> “In both patients and rats with MASLD, lanifibranor treatment was associated with improvement in liver endothelial phenotype.”

Source: [Rautou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12142333/)

<a id="topic-2.1.2.6.2-10"></a>

### Portal pressure and fibrosis in cirrhotic rat models

> “TAA-cirrhotic rats receiving lanifibranor showed significantly lower portal pressure compared with vehicle-treated animals (-15%; p = 0.003) without decreasing portal blood flow, indicating improved hepatic vascular resistance.”
> “Moreover, lanifibranor-treated TAA-rats showed decreased ascites, improved LSEC and HSC phenotypes, ameliorated hepatic microvascular function, reduced hepatic inflammation, and significant fibrosis regression (-32%; p = 0.020).”

Source: [Boyer-Diaz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33278455/)

<a id="topic-2.1.2.6.2-11"></a>

### Electrocardiographic findings in healthy volunteers and patients with type 2 diabetes

> “In clinical trials performed in healthy volunteers and patients with type 2 diabetes, lanifibranor was safe and well tolerated.”
> “There were no clinically relevant time or dose-related changes on cardiac and muscle markers, liver enzymes or markers of renal function.”
> “The 12-lead electrocardiogram (ECG) did not show clinically significant changes.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

Additional sources: [Sabatini and Gastaldelli (2025)](https://pubmed.ncbi.nlm.nih.gov/40089070/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
